ArticleOdontology2026
Preparation of apigenin-loaded microspheres and their effects against Porphyromonas gingivalis.
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Periodontal disease is a leading cause of tooth loss in adults, and current drug treatments are limited by issues such as drug resistance and short duration of action. This study aimed to prepare apigenin-loaded PLGA microspheres (AM) with sustained-release properties and evaluate their physicochemical characteristics as well as their antibacterial and anti-biofilm activities against Porphyromonas gingivalis, a key pathogen in periodontitis. AM were prepared using a solvent evaporation method and characterized by scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), and drug release studies. The minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), minimum biofilm inhibitory concentration (MBIC), and minimum biofilm eradication concentration (MBEC) of AM against Porphyromonas gingivalis were determined. Biofilm disruption was visualized by confocal laser scanning microscopy (CLSM) and SEM, and the expression of virulence factor genes was analyzed by RT-qPCR. AM exhibited a regular spherical shape with an average particle size of 44.7 μm, a drug loading capacity of 10.43%, and an encapsulation efficiency of 78.22%. FTIR and XRD confirmed the successful encapsulation of apigenin, and the drug release profile demonstrated sustained-release characteristics. The MIC, MBC, MBIC, and MBEC of AM against Porphyromonas gingivalis were 3, 6.5, 4, and 7 mg/mL, respectively. CLSM and SEM revealed that AM disrupted biofilm integrity and caused damage to bacterial cell membranes. RT-qPCR showed significant downregulation of the virulence factor genes hagA, rgpA, and kgp (P < 0.05). This study successfully developed sustained-release apigenin-loaded PLGA microspheres (AM) that exert effective suppression of Porphyromonas gingivalis through combined antibacterial, anti-biofilm, and anti-virulence mechanisms.
Indexed as
Identifiers
42265502What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.